STALICLA announced today that Lynn Durham, CEO and Founder, is scheduled to present at the 11th SACHS Associates 11th Annual Life Sciences CEO Forum being held February 26-27 in Zurich, Switzerland.
STALICLA is proud to announce the successful closure of its initial round of financing at CHF 4M, committed from Biotech experienced investors. This round of funding will be used to advance STALICLA’s therapeutic towards clinical trial, as well as advancing ASD research using the innovative Databased Endophenotyping Patient Identification technology. With this investment, STALICLA is also looking to expand the team in order to support the ongoing research and future commercialization of identified therapeutics.
STALICLA is proud to announce its selection on JPM UK Private Bank start-up ticket. Lynn Durham, CEO and Founder, is scheduled to present to the Healthcare Executive team during the 36th Annual JPM Healthcare conference, being held January 8-11, 2018 in San Francisco. Lynn’s presentation on the company’s strategy and development pipeline will take place on Tuesday 9th of January 2018 at 14:00 pm EST, 6th floor Westin St-Francis room.
STALICLA is excited to announce a long-term research partnership with the Greenwood Genetic Center (GGC), a leading translational research center for neurodevelopmental disorders, including autism spectrum disorder (ASD).
Lynn Durham, CEO & Founder, is participating in patient focused Drug Development meeting organized by FDA being held May 4, 2017.